Subject index of volume 23

Antibody
- anti-CEA 101, 107, 119, 137
- anti-cystic fluid 143
- anti-human AFP 81
- dependent cellular cytotoxicity 56
- monoclonal 31, 93, 101, 107, 119, 148
Antigen
- CEA 101, 107, 119, 137
- HLA-DR 155
- melanoma associated 93

BCG 155
BCNU 87
Bestatin 5
Bleomycin 46
Breast cancer 31, 143, 169, 217

Carcinogenesis
- chemical 130
Cervix carcinoma 56
Colon tumor 101, 107
Colorectal carcinoma 119
Corynebacterium parvum 1, 179, 214
Cyclophosphamide 11
Cytotoxic factor 60

Fibroblast-derived inhibitory factor 60

Gastric carcinoma 119

Hybridoma
- human 31

Immune complexes 51
Immune regulation 67
Immune surveillance 78, 79
Immunity
- antitumor 11
Immunochemotherapy 81
Immunological surveillance 130
Immunotherapy 5, 25, 165, 192
- BCG 155
Interferon inducers 179
Interferons 41, 56, 217
Interleukin 2 25, 165

Kupffer cells 214

Leukemia 5, 87
Lung tumor 1, 200
Lymphocyte
- activated killer 207
- cytotoxic T 113
- Lyt-1+2 73
- tumor infiltrating 169
Lymphoma 51

Macrophage 60
- activated 41, 46, 200
- cytotoxic 113
- tumor associated 67
Melanoma 155
Metastasis 179
- adenocarcinoma 137
- breast carcinoma 143
- liver 214
Monoclonal antibody 93, 101, 107, 119
- BW 494 185
- human 31
- localization 148
MOPC-315 11
Myeloma X5563 25

Natural resistance 78, 79
Neuraminidase 192
NK cells 56

OK-432 207

Pancreatic carcinoma 185
Pleural effusions 51

Radiation 20
Reovirus 87

Sarcoma 148

Trehalose dimycolate 200
Tumor
- canine 192
- immunosensitivity 46
- inhibition 179
- localization 107, 119
- lymphocytes 169
- neutralization 113
- rejection 159
- spheroid 20
Tumor type
- breast 31, 143, 169, 217
- cervix 56
- colon 101, 107
- colorectal 119
- gastric 119
- leukemia 5, 87
- lung 1, 200
- lymphoma 51, 179
- melanoma 155
- MOPC-315 1
- myeloma-X5563 25
- pancreatic 148
- yolk sac 181

Vaccinia virus

Winn test 73, 113

Yolk sac tumor 81

Contents of volume 23

No. 1 (pp 1–80) published September 1986
No. 2 (pp 81–158) published October 1986
No. 3 (pp 159–220) published November 1986

This volume contains the supplement
12th Annual Meeting (Abstracts)
of the European Society for Medical Oncology
Nice, November 28–30, 1986
A1–A80 (316 Abstracts)

Allum WH → Macdonald F, et al. 119
Anderson J → Pearson HJ, et al. 214
Ashford R, Priestman T, Mott T, Bottomley M: Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer 217

Bagshawe KD → Rogers GT, et al. 107
Barker E → Mokyr MB 11
Bell PRF → Pearson HJ, et al. 214
Blend M → Greager JA, et al. 148
Boden J → Rogers GT, et al. 107
Bosslet K, Kern HF, Kanzy EJ, Steinstraesser A, Schwarz A, Lüben G, Schorlemmer HU, Sedlacek HH: A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas 185
Bottomley M → Ashford R, et al. 217
Bröcker EB, Suter L, Czarnetzki BM, Macher E: BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors? 155
Brown JM → Greager JA, et al. 148

Chamberlain J → Pearson HJ, et al. 214
Cox DC → Williams ME, et al. 87
Crowson MC → Macdonald F, et al. 119
Czarnetzki BM → Bröcker EB, et al. 155

Das Gupta TK → Greager JA, et al. 148
Davis S → Huberman MS, et al. 137
Davis S → Estabrook, et al. 143
Den Otter W: *Reply* 79
Den Otter W → Dullens HFJ, et al. 113
Den Otter W → Dullens HFJ, et al. 159
De Weger RA → Dullens HFJ, et al. 159
Dougherty GJ, McBride WH: Immunoregulating activity of tumor-associated macrophages 67
Duewell S, Horst W, Westera G: Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose 101
Dullens HFJ, Vuist W, Van der Maas M, Den Otter W: The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice 113
Dullens HFJ, Van der Tol MWM, De Weger RA, Den Otter W: A survey of some formal models in tumor immunology 159

Eggermont AMM → Steller EP, et al. 165
Estabrook A, Kister SJ, Hardy MA, Grossbard L, Oster MW, Davis S, Mazoujian G, Haagensen DE, Jr: Non-human primate (Baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma 143

Fielding JWL → Macdonald F, et al. 119
Fliedner V von → Whiteside TL, et al. 169

Gallily R, Gifford GE, Loewenstein J: Suppression of both macrophage-mediated tumor cell lysis and cytolytic factor production by a factor (CIF) derived from normal embryonic fibroblasts 60
Garcia JL → Greager JA, et al. 148
Gifford GE → Gallily R, et al. 60
Golubić M → Trutin-Ostović C, et al. 130
Greager JA, Brown JM, Pavel DG, Garcia JL, Blend M, Das Gupta TK: Localization of human sarcoma with radiolabeled monoclonal antibody. A preliminary study 148
Grimm EA → Yagita M 207
Grossbard L → Estabrook A, et al. 143
Gu H-X → Wakamiya N, et al. 125

Haagensen DE, Jr → Huberman MS, et al. 137
Haagensen DE, Jr → Estabrook A, et al. 143
Hagmayer G → Sedlacek HH, et al. 192
Hara T → Ohkawa K, et al. 81
Harada M → Maekawa R, et al. 25
Hardy MA → Estabrook A, et al. 143
Harwood PJ → Rogers GT, et al. 107
Hibi N → Ohkawa K, et al. 81
Hill T → Huberman MS, et al. 137
Horst W → Duewell S, et al. 101
Hosokawa M → Xu Z-Y, et al. 46
Huberman MS, Lokich JJ, Hill T, Kaldany A, Kassis A, Price T, Moore C, Davis S, Kasulis P, Monaco AP, Haagensen DE, Jr: Non-human primate (Baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study 137
Hurlimann J → Whiteside TL, et al. 169

Imai H → Wakamiya N, et al. 125
Iwaguchi T → Ozawa H, et al. 73

Kaldany A → Huberman MS, et al. 137
Kanzy EJ → Bosslet K, et al. 185
Kassis A → Huberman MS, et al. 137
Kasulis P → Huberman MS, et al. 137
Kataoka T → Ozawa H, et al. 73
Kato S → Wakamiya, et al. 125
Kern HF → Bosslet K, et al. 185
Kirchner H → Storch E, et al. 179
Kister SJ → Estabrook A, et al. 143
Kitagawa T → Maekawa R, et al. 25
Kobayashi H → Xu Z-Y, et al. 46
Kripke ML: *Letter to the editors* 78
Kurita S → Ota K, et al. 5

Lepoivre M → Nolibe D, et al. 200
Life P → Macdonald F, et al. 119
Loewenstein J → Gallily R, et al. 60
Lokich JJ → Huberman MS, et al. 137
Lord EM → Wilson KM 20
Lüben G → Bosslet K, et al. 185

Macdonald F, Crowson MC, Allum WH, Life P, Fielding JWL: In vivo studies on the uptake of radiolabelled antibodies by colorectal and gastric carcinoma xenografts 119
Macher E → Bröcker EB, et al. 155
Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K: Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563 25
Marušić M → Trutin-Ostović C, et al. 130
Masaoka T → Ota K, et al. 5
Masse R → Nolibe D, et al. 200
Matović M → Trutin-Ostović C, et al. 130
Matthews W → Steller EP, et al. 165

Matsumoto M → Maekawa R, et al. 25
Mazoujian G → Estabrook A, et al. 143
McBride WH → Dougherty GJ 67
Miescher S → Whiteside TL, et al. 169
Mokyr MB, Barker E: Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers 11
Monaco AP → Huberman MS, et al. 137
Moore C → Huberman MS, et al. 137
Moretta L → Whiteside TL, et al. 169
Morikawa K → Xu Z-Y, et al. 46
Mott T → Ashford R, et al. 217

Nadkarni GR → Patel GV, et al. 51
Nadkarni JJ → Patel GV, et al. 51
Nadkarni JJ → Satam MN, et al. 56
Nagao S-I, Sato K, Osada Y: Synergistic induction of cytotoxicity in macrophages by murine interferon-γ and biological response modifiers derived from microorganisms 41
Nolibe D, Masse R, Tenu J-P, Lepoivre M, Petit J-F: Activation of rat alveolar macrophages and protection against i.v. injected tumor cells by intratracheal administration of trehalose dimycolate 200

Ogawa N → Ota K, et al. 5
Ohkawa K, Tsukada Y, Hibi N, Umemoto N, Hara T: Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human α-fetoprotein conjugated with mitomycin C via human serum albumin 81
Osada Y → Nagao S-I, et al. 41
Oster MW → Estabrook A, et al. 143
Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N: Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults 5
Ozawa H, Iwaguchi T, Kataoka T: The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice 73

Patel GV, Satam MN, Nadkarni GR, Nadkarni JJ: Isolation and dissociation of immune complexes from pleural effusions of lymphoma patients 51
Pavel DG → Greager JA, et al. 148
Pearson HJ, Anderson J, Chamberlain J, Bell PRF: The effect of Kupffer cell stimulation or depression on the development of liver metastases in the rat 214
Pedley RB → Rogers GT, et al. 107
Petit J-F → Nolibe D, et al. 200
Price T → Huberman MS, et al. 137
Priestman T → Ashford R, et al. 217

Rogers GT, Pedley RB, Boden J, Harwood PJ, Bagshawe KD: Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localisation and tissue distribution in nude mice xenografted with human colon carcinoma 107
Rümke P → Vennegoor C 93

Satam MN → Patel GV, et al. 51
Satam MN, Suraiya JN, Nadkarni JJ: Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients 56
Sato K → Maekawa R, et al. 25
Sato K → Nagao S-I, et al. 41
Schirrmacher V → Storch E, et al. 179
Schorlemmer HU → Bosslet K, et al. 185
Schwarz A → Bosslet K, et al. 185
Sedlacek HH → Bosslet K, et al. 185
Sedlacek HH, Hagmayer G, Seiler FR: Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors 192
Seiler FR → Sedlacek HH, et al. 192
Steinstraesser A → Bosslet K, et al. 185
Steller EP, Eggermont AMM, Matthews W, Sugarbaker PH: Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2 165
Stevenson JR → Williams ME, et al. 87
Storch E, Kirchner H, Schirrmacher V: Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with *Corynebacterium parvum* 179
Strelkauskas AJ, Taylor CL: Human monoclonal antibody. Construction of stable clones reactive with human breast cancer 31
Sugarbaker PH → Steller EP, et al. 165
Suraiya JN → Satam MN, et al. 56
Suter L → Bröcker EB, et al. 155

Taylor CL → Strelkauskas AJ 31
Tenu J-P → Nolibe D, et al. 200
The Ludwig Lung Cancer Study Group: Intrapleural and intravenous *Corynebacterium parvum* in patients with resected stage I and II non-small cell carcinoma of the lung 1
Trutin-Ostović C, Golubić M, Matović M, Marušić M: Incidence and growth of methylcholanthrene-induced tumors in mice with altered immunological status 130
Tsukada Y → Ohkawa K, et al. 81

Ueda S → Wakamiya N, et al. 125
Umemoto N → Ohkawa K, et al. 81
Uzuka Y → Ota K, et al. 5

Van der Maas M → Dullens HFJ, et al. 113
Van der Tol MWM → Dullens HFJ, et al. 159
Vennegoor C, Rümke P: Circulating melanoma-associated antigen detected by monoclonal antibody NKI/C-3 93
Vuist W → Dullens HFJ, et al. 113

Wakamiya N, Wang Y-L, Imai H, Gu H-X, Ueda S, Kato S: Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity 125
Wang Y-L → Wakamiya N, et al. 125
Westera G → Duewell S, et al. 101
Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V: Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas 169
Williams ME, Cox DC, Stevenson JR: Rejection of reovirus-treated L1210 leukemia cells by mice 87
Wilson KM, Lord EM: Effects of radiation on host-tumor interactions using the multicellular tumor spheroid model 20

Xu Z-Y, Hosokawa M, Morikawa K, Kobayashi H: Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin 46

Yagita M, Grimm EA: Inhibition of in vitro LAK generation by OK-432 207
Yamada K → Ota K, et al. 5